AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2025

Feb 11, 2025

6965_dirs_2025-02-11_f7b56040-aebe-4810-8ac6-64c4a2754f69.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-02-11

Reporting Person: Gabay Avraham (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-11	Common Stock	A	34000	—	Acquired	392040	Direct
2025-02-11	Common Stock	A	42000	—	Acquired	434040	Direct

Footnotes

F1: Represents shares issued on settlement of performance stock units ("PSUs") previously granted on June 20, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria.

F2: Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria.